Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cerus Corp (CERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 905,894
  • Shares Outstanding, K 133,810
  • Annual Sales, $ 51,330 K
  • Annual Income, $ -60,590 K
  • 36-Month Beta 1.51
  • Price/Sales 17.65
  • Price/Cash Flow N/A
  • Price/Book 10.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.71 +16.11%
on 10/11/18
7.54 -12.07%
on 09/25/18
-0.68 (-9.30%)
since 09/19/18
3-Month
5.71 +16.11%
on 10/11/18
8.05 -17.64%
on 08/03/18
-0.82 (-11.01%)
since 07/19/18
52-Week
2.75 +141.09%
on 11/02/17
8.05 -17.64%
on 08/03/18
+3.63 (+121.00%)
since 10/19/17

Most Recent Stories

More News
Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet, and Francesca's -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cerus Corporation (NASDAQ:CERS),...

ONCE : 47.76 (-4.23%)
IMPV : 55.30 (-0.11%)
FRAN : 2.80 (-10.26%)
CENTA : 29.94 (-0.73%)
CERS : 6.63 (-2.07%)
ASIX : 29.49 (-0.47%)
Cerus Corp has the Best Relative Performance in the Health Care Supplies Industry (CERS , STAA , ALGN , MMSI , NEOG )

Here are the top 5 stocks in the Health Care Supplies industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

STAA : 40.54 (-3.98%)
ALGN : 312.79 (-3.18%)
CERS : 6.63 (-2.07%)
Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting

Cerus Corporation (Nasdaq: CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston.

CERS : 6.63 (-2.07%)
Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting

Cerus Corporation (Nasdaq: CERS) announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October...

CERS : 6.63 (-2.07%)
Relatively Good Performance Detected in Shares of Staar Surgical in the Health Care Supplies Industry (STAA , HAE , CERS , NEOG , MMSI )

Here are the top 5 stocks in the Health Care Supplies industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

STAA : 40.54 (-3.98%)
CERS : 6.63 (-2.07%)
HAE : 106.31 (-2.03%)
Dr. Laurence Corash Recognized With the Prestigious Dale A. Smith Memorial Award

Cerus Corporation (Nasdaq: CERS) today announced Dr. Laurence Corash, the Company's co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by...

CERS : 6.63 (-2.07%)
Cerus Appoints Eric Bjerkholt to Board of Directors

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Eric Bjerkholt to its Board of Directors. Mr. Bjerkholt currently serves as the chief financial officer of Aimmune Therapeutics,...

AIMT : 27.29 (-1.52%)
CERS : 6.63 (-2.07%)
Cerus to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that William 'Obi' Greenman, Cerus' president and chief executive officer, will present and provide a corporate update at the Cantor Fitzgerald...

CERS : 6.63 (-2.07%)
Cerus Appoints Timothy L. Moore to Board of Directors

Cerus Corporation (Nasdaq:CERS) today announced the appointment of Timothy L. Moore to its Board of Directors. Mr. Moore, who currently serves as executive vice president, technical operations...

CERS : 6.63 (-2.07%)
New Research Coverage Highlights Evertec, Cerus, REV Group, U.S. Silica, The Manitowoc, and World Fuel Services -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evertec, Inc. (NYSE:EVTC),...

EVTC : 24.93 (+1.55%)
SLCA : 16.07 (-0.62%)
MTW : 19.43 (-5.50%)
REVG : 12.82 (-1.23%)
CERS : 6.63 (-2.07%)
INT : 27.78 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CERS with:

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Key Turning Points

2nd Resistance Point 6.96
1st Resistance Point 6.80
Last Price 6.63
1st Support Level 6.54
2nd Support Level 6.44

See More

52-Week High 8.05
Last Price 6.63
Fibonacci 61.8% 6.03
Fibonacci 50% 5.40
Fibonacci 38.2% 4.77
52-Week Low 2.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar